SG11201901611YA - Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof - Google Patents

Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof

Info

Publication number
SG11201901611YA
SG11201901611YA SG11201901611YA SG11201901611YA SG11201901611YA SG 11201901611Y A SG11201901611Y A SG 11201901611YA SG 11201901611Y A SG11201901611Y A SG 11201901611YA SG 11201901611Y A SG11201901611Y A SG 11201901611YA SG 11201901611Y A SG11201901611Y A SG 11201901611YA
Authority
SG
Singapore
Prior art keywords
international
singapore
methods
identification
disease
Prior art date
Application number
SG11201901611YA
Inventor
Florent Ginhoux
Chi Ee Peter See
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201901611YA publication Critical patent/SG11201901611YA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIPO I PCT mu °million °nolo olomomiollionoiflo ois (10) International Publication Number WO 2018/044238 Al (51) International Patent Classification: G01N 33/50 (2006.01) A61P 31/12 (2006.01) G01N 33/68 (2006.01) A61P 3/04 (2006.01) G01N 33/564 (2006.01) A61P 29/00 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) A61K 35/15 (2015.01) A61P 37/00 (2006.01) (21) International Application Number: PCT/SG2017/050435 (22) International Filing Date: Immunology Network, 8A Biomedical Grove, #04-06 Im- munos, Singapore 138648 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 31 August 2017 (31.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201607246S 31 August 2016 (31.08.2016) SG 10201703621Q 03 May 2017 (03.05.2017) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). = (72) Inventors: GINHOUX, Florent; c/o Singapore Immunol- ogy Network, 8A Biomedical Grove, #04-06 Immunos, Sin- gapore 138648 (SG). SEE, Chi Ee Peter; c/o Singapore (54) Title: METHODS FOR THE IDENTIFICATION, TARGETING AND ISOLATION OF HUMAN DENDRITIC CELL (DC) PRECURSORS \"PRE-DC\" AND THEIR USES THEREOF FIG. 31 (57) : Biomarkers for the detection and identification of a pre- cursor of conventional dendritic cell (cDC) (pre-DC) and its cell sub- sets (pre-cDC1 or pre-cDC2), are defined, which include CD169, CD327, AXL, CD271, CD324 and combinations thereof for detecting pre-DCs. Methods for detecting a disease or condition, prognosis of an existing disease or condition comprising determining the number of pre-DC cells in sample from a subject as compared to control, as well as methods of treating a patient comprising administration of antibodies against CD169, CD327, AXL, CD271, CD324 and combinations thereof are also dis- closed. In addition, an immunogenic composition comprising one or more binding molecules specific for one or more biomarkers or antigen of a target disease and/or one or more cells selected from the group consisting of early pre-DC, pre-cDC1 and pre-cDC2 are also disclosed for eliciting an immune response against an infectious disease or cancer. W O 20 18/0 44238 Al [Continued on next page] WO 2018/044238 Al MIDEDIMOMMIDIRMOINNHOEHOMMOMEEM TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3))
SG11201901611YA 2016-08-31 2017-08-31 Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof SG11201901611YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201607246S 2016-08-31
SG10201703621Q 2017-05-03
PCT/SG2017/050435 WO2018044238A1 (en) 2016-08-31 2017-08-31 Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof

Publications (1)

Publication Number Publication Date
SG11201901611YA true SG11201901611YA (en) 2019-03-28

Family

ID=61309054

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202101958YA SG10202101958YA (en) 2016-08-31 2017-08-31 Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof
SG11201901611YA SG11201901611YA (en) 2016-08-31 2017-08-31 Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202101958YA SG10202101958YA (en) 2016-08-31 2017-08-31 Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof

Country Status (5)

Country Link
US (1) US11249081B2 (en)
EP (1) EP3507601B1 (en)
CN (1) CN109906381B (en)
SG (2) SG10202101958YA (en)
WO (1) WO2018044238A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202004426SA (en) * 2017-11-17 2020-06-29 Merck Sharp & Dohme Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
CN110389221B (en) * 2019-08-30 2021-03-16 广州中科蓝华生物科技有限公司 Combined formula kit for analyzing phenotype and function of CD1c + dendritic cell subset and application thereof
CN110922478B (en) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 Fully human monoclonal antibody against chikungunya fever and application thereof
CN113218848B (en) * 2021-04-30 2022-08-12 天津深析智能科技发展有限公司 Method for judging non-specific cell population

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002305452A1 (en) * 2001-05-08 2002-11-18 Emory University Regulating immine responses using dendritic cells
CN101035807A (en) 2004-06-09 2007-09-12 泰勒公司 Diagnosis and treatment of SIGLEC-6 associated diseases
JP2008502368A (en) 2004-06-09 2008-01-31 タノックス， インコーポレイテッド Diagnosis and treatment of SIGLEC-6 related diseases
EP2582729A4 (en) * 2010-06-18 2014-05-28 Hoffmann La Roche Anti-axl antibodies and methods of use
EP2611464B1 (en) * 2010-09-03 2018-04-25 AbbVie Stemcentrx LLC Novel modulators and methods of use
GB201104469D0 (en) * 2011-03-17 2011-04-27 Univ Gent Control of phagocytosis
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
EP2950095B1 (en) * 2014-05-28 2018-08-29 Technische Universität Dresden Cell-based assay and screening methods for modulators of p75NTR signaling
PT3169706T (en) 2014-07-11 2020-03-13 Genmab As Antibodies binding axl
WO2016049641A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016130489A1 (en) * 2015-02-09 2016-08-18 Slingshot Biosciences, Inc. Hydrogel particles with tunable optical properties and methods for using the same
WO2018035364A1 (en) * 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses

Also Published As

Publication number Publication date
EP3507601A1 (en) 2019-07-10
CN109906381A (en) 2019-06-18
CN109906381B (en) 2023-03-31
US11249081B2 (en) 2022-02-15
EP3507601B1 (en) 2023-08-16
EP3507601A4 (en) 2020-08-05
SG10202101958YA (en) 2021-03-30
WO2018044238A1 (en) 2018-03-08
US20190324038A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201908396PA (en) Methods of treating tumor
SG11201807334SA (en) Methods, compositions, and devices for information storage
SG11201901126UA (en) Combination therapy for cancer
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201901611YA (en) Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof
SG11201901371XA (en) Methods for the detection of genomic copy changes in dna samples
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201900442PA (en) Sorting of t lymphocytes in a microfluidic device
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201811408PA (en) Adoptive cell transfer and oncolytic virus combination therapy
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201809996QA (en) Ribonucleic acid (rna) interactions
SG11201806946VA (en) Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma
SG11201908767QA (en) Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201808573YA (en) Nucleic acid stabilization reagent, kits, and methods of use thereof
SG11201910206QA (en) Methods and compositions for treating inflammatory gastrointestinal disorders
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof